Neurogene(NGNE) - 2024 Q1 - Quarterly Results

Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates Presented favorable safety data from Phase 1/2 NGN-401 gene therapy trial for Rett syndrome at ASGCT Annual Meeting Received Australian HREC approval for NGN-401 trial Remains on track to provide interim NGN-401 efficacy data from Cohort 1 in 4Q:24 Strong balance sheet with cash runway into 2H:26 NEW YORK – May 10, 2024 – Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicine ...